Alisertib
3rd-line+ Extensive-Stage Small Cell Lung Cancer (SCLC)
Key Facts
About Puma Biotechnology
Puma Biotechnology is a U.S.-based, commercial-stage oncology company with a proven strategy of in-licensing and developing targeted cancer therapies. Its flagship product, NERLYNX, generates revenue for the extended adjuvant treatment of HER2-positive early breast cancer. The company is advancing alisertib, an Aurora A kinase inhibitor, in pivotal trials for small cell lung cancer and metastatic breast cancer, aiming to diversify its revenue base. Puma's inclusion in the NASDAQ Biotechnology Index underscores its transition to a sustainable commercial entity.
View full company profileAbout Puma Biotechnology
Puma Biotechnology is a U.S.-based, commercial-stage oncology company with a proven strategy of in-licensing and developing targeted cancer therapies. Its flagship product, NERLYNX, generates revenue for the extended adjuvant treatment of HER2-positive early breast cancer. The company is advancing alisertib, an Aurora A kinase inhibitor, in pivotal trials for small cell lung cancer and metastatic breast cancer, aiming to diversify its revenue base. Puma's inclusion in the NASDAQ Biotechnology Index underscores its transition to a sustainable commercial entity.
View full company profile